ENDOD1: A Potential Drug Target and Biomarker (G23052)
ENDOD1: A Potential Drug Target and Biomarker
Endod1, also known as ENDD1, is a gene that encodes a protein with unique properties, making it an attractive candidate for drug development as well as a diagnostic biomarker. The protein produced by ENDOD1 has been shown to play a crucial role in the development and progression of various diseases, including cancer.
The unique features of ENDOD1 are its novel domain, which is composed of 111 amino acids and is characterized by a unique hydrophobic core and a hydrophilic tail. This unique structure has been shown to give ENDOD1 a unique stability and stability in various cellular environments, including in the cytosol and in the endoplasmic reticulum (ER), which are both essential for the stability of proteins.
ENDOD1 has also been shown to have a unique stability in the presence of various drug treatments, making it a potential drug target. For instance, ENDOD1 has been shown to be highly resistant to the drug inhibitors used to treat various diseases, including cancer. This resistance has been attributed to the unique structure of ENDOD1, which has been shown to prevent the binding of inhibitors to the protein.
In addition to its potential as a drug target, ENDOD1 has also been shown to be a potential biomarker for various diseases, including cancer. The reason for its potential as a biomarker is its expression and sensitivity to various diseases, including cancer.
ENDOD1 has been shown to be highly expressed in various tissues and organs, including the brain, liver, and muscle. This high expression has been associated with the development and progression of various diseases, including cancer. Additionally, ENDOD1 has also been shown to be sensitive to various diseases, including cancer, which suggests that its levels may be a useful indicator of disease status.
In conclusion, ENDOD1 is a unique and promising candidate for drug development as well as a biomarker for various diseases. Its unique properties, including its hydrophobic core and unique stability, make it an attractive target for drug development. Additionally, its expression and sensitivity to various diseases make it a potential biomarker for cancer and other diseases. Further research is needed to fully understand the potential of ENDOD1 as a drug target and biomarker.
Protein Name: Endonuclease Domain Containing 1
Functions: May act as a DNase and a RNase. Plays a role in the modulation of innate immune signaling through the cGAS-STING pathway by interacting with RNF26
More Common Targets
ENDOG | Endogenous Retrovirus group K Env polyprotein (ERVK) | Endogenous retrovirus group K member 25 Pol protein-like, transcript variant X1 | EndoGlyx-1 | Endoplasmic reticulum collagen prolyl 3-hydroxylation complex | Endothelin receptor | Endothelin-Converting Enzymes (ECE) | Endothiapepsin | ENDOU | ENDOV | ENG | ENGASE | ENHO | ENKD1 | ENKUR | ENO1 | ENO1-AS1 | ENO1P1 | ENO1P4 | ENO2 | ENO3 | ENO4 | ENOPH1 | eNoSC Complex | ENOSF1 | ENOX1 | ENOX1-AS2 | ENOX2 | ENPEP | ENPP1 | ENPP2 | ENPP3 | ENPP4 | ENPP5 | ENPP6 | ENPP7 | ENPP7P10 | ENPP7P12 | ENPP7P7 | ENSA | ENSAP2 | ENTHD1 | ENTPD1 | ENTPD1-AS1 | ENTPD2 | ENTPD3 | ENTPD3-AS1 | ENTPD4 | ENTPD5 | ENTPD6 | ENTPD7 | ENTPD8 | ENTR1 | ENTREP1 | ENTREP2 | ENTREP3 | env | ENY2 | EOGT | EOLA1 | EOLA1-DT | EOLA2 | EOLA2-DT | EOMES | EP300 | EP300-AS1 | EP400 | EP400P1 | EPAS1 | EPB41 | EPB41L1 | EPB41L1-AS1 | EPB41L2 | EPB41L3 | EPB41L4A | EPB41L4A-AS1 | EPB41L4A-DT | EPB41L4B | EPB41L5 | EPB42 | EPC1 | EPC2 | EPCAM | EPCAM-DT | EPDR1 | EPG5 | EPGN | EPHA1 | EPHA1-AS1 | EPHA10 | EPHA2 | EPHA2-AS1 | EPHA3 | EPHA4 | EPHA5 | EPHA5-AS1 | EPHA6 | EPHA7 | EPHA8 | EPHB1